Journal of Clinical and Aesthetic Dermatology

DEC 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link:

Contents of this Issue


Page 53 of 59

JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY December 2017 • Volume 10 • Number 12 54 of genetic diseases," said Lynn Petukhova, an assistant professor in the Department of Dermatology at the College of Physicians & Surgeons. * For more information: releases/2017/11/171127152035.htm WHY PROBIOTIC SKIN CARE IS WORTH IT, ACCORDING TO EXPERTS Experts weighed in on the recent probiotic craze, stating that probiotics can help protect the skin in a variety of ways, such as acting as a "protective shield by preventing bad microorganisms from provoking an immune reaction." They're also able to recalibrate the skin microbiome and can be especially beneficial to people with chronic inflammation. * For more information: releases/2017/11/171127152035.htm EXCESS WEIGHT MIGHT RAISE ROSACEA RISK A 14-year study of almost 90,000 women found that patients with a body mass index (BMI) greater than 35 resulted in a 48-percent higher chance of developing rosacea. For comparison, a BMI of 30 and up is considered obese. The research was published in the Journal of the American Academy of Dermatology in the December issue. * For more information: https://health. excess-weight-may-raise-rosacea-risk PRESCRIPTION DERMATOLOGY THERAPEUTICS MARKET IS SET TO GARNER STAGGERING REVENUES BY 2024 Skin is the largest organ of the body, and the first point of contact for microbes and toxins, any functional issue with it makes the person pay high prices for it. It contains a rich habitat of microbes, which results in various dysfunctions, and this is the point where dermatology steps in. The importance of skin has increased in the recent years. High range of population is willing to treat various dermatological diseases due to awareness. Expansion of the number of indications treated by topical drugs is likely to drive the growth of the dermatology drugs market. * For more information: hhttp://www. dermatology-therapeutics-market-is-set-to- garner-staggering-revenues-by-2024/ CAN ELMER'S GLUE REMOVE BLACKHEADS? DERMATOLOGISTS WEIGH IN Dermatologists provided mixed reactions to the idea that applying glue to one's face could eliminate blackheads. While one dermatologist noted that this method is technically safe because of the glue's acrylates that are frequently used in "do-it-yourself " masks, another dermatologist said the glue can actually cause skin irritation and even an allergic reaction. * For more information: https://www. glue-dermatologists ATHENEX ANNOUNCES ACCEPTANCE OF PHASE II DATA OF KX2-391 FOR THE TREATMENT OF ACTINIC KERATOSIS Athenex Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, announced that an abstract for the data from the Phase II study of KX2-391 in 168 patients with actinic keratosis has been accepted for oral presentation and online ePoster at the American Academy of Dermatology Annual Meeting in San Diego on February 17, 2018. * For more information: release/2017/11/28/1206849/0/en/ Athenex-Announces-Acceptance-of-Phase-II- Data-of-KX2-391-for-the-Treatment-of-Actinic- Keratosis-for-Presentation-at-the-American- Academy-of-Dermatology-Meeting-on- February-17-2018.html BREAST-FEEDING IN INFANC Y LINKED TO DECREASED RISK OF ECZEMA IN TEENS Research published in JAMA Pediatrics found that consistent and exclusive breastfeeding during the infancy stage can reduce the chance of the child developing eczema as a teenager. Children in the control group had a 0.7-percent prevalence of eczema, while the intervention group had just a 0.3 percent prevalence. * For more information: https:// news/online/%7B52cf30bd-044c-4c17-828d- 9983978dd2a8%7D/breast-feeding-in-infancy- linked-to-decreased-risk-of-eczema-in-teens NOVARTIS' COSENT YX® IS FIRST BIOLOGIC TO SHOW LONG-TERM EFFICAC Y IN NAIL AND PALMOPLANTAR PSORIASIS Novartis announced first-of-its-kind long-term data showing that Cosentyx® (secukinumab) provided sustained improvements in nail and palmoplantar psoriasis out to 2.5 years. These data are unique, as it is the first time any biologic has demonstrated long-term efficacy and safety in nail and palmoplantar psoriasis. These new data from a clinical study were presented at the 8th International Congress of Psoriasis from Gene to Clinic in London, UK. * For more information: release/2017/11/30/1211681/0/en/ Novartis-Cosentyx-is-first-biologic-to-show- long-term-efficacy-in-nail-and-palmoplantar- psoriasis-which-can-impact-up-to-90-of- psoriasis-patients.html BIOSTEM TECHNOLOGIES INC. ANNOUNCES A PRE-CLINICAL STUDY OF BSEM17-115 AT UNIVERSIT Y OF MIAMI BioStem Technologies Inc., in collaboration with the University of Miami's Department of Dermatology and Cutaneous Surgery Wound Healing Research Laboratory, has launched a study to examine the effects of the Company's "BSEM17-115" proprietary compound on the healing of third degree burn wounds. * For more information: release/2017/12/11/1250861/0/en/BioStem- Technologies-Inc-Announces-a-Pre-Clinical- Study-of-BSEM17-115-at-University-of-Miami. html N E W S & T R E N D S

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - DEC 2017